UnitedHealth Group vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Minnetonka US largest healthcare company (NYSE: UNH) at $400.3B 2024 revenue with UnitedHealthcare + Optum; 2025 leadership transition (Hemsley return, Witty departure) and suspended outlook after Change Healthcare breach and elevated medical costs.
About
UnitedHealth Group is a Minnetonka, Minnesota-based healthcare and insurance conglomerate — publicly traded on the New York Stock Exchange (NYSE: UNH) as the largest healthcare company in the United States by revenue — reporting $400.3 billion in 2024 revenues and operating through two complementary platforms: UnitedHealthcare (health insurance serving 50+ million people) and Optum (health services including OptumHealth care delivery, OptumRx pharmacy benefit management, and OptumInsight technology and analytics). Employing approximately 400,000 people globally across 500+ locations, UnitedHealth Group has been transformed by a turbulent 2024-2025 period: the Change Healthcare ransomware cyberattack (February 2024) disrupted healthcare payments for 190 million Americans; UnitedHealthcare CEO Brian Thompson was murdered in December 2024 in New York City; and CEO Andrew Witty resigned for personal reasons in May 2025, with founder-era CEO Stephen Hemsley returning to lead the company and the 2025 earnings outlook suspended amid higher-than-expected medical costs.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.